DreamTeamNetwork (DTN) is proud to announce its role as a platinum-level sponsor for the upcoming 2016 Disruptive Growth & Healthcare Conference, hosted by Source Capital Group, taking place in New York City February 10-11.

As a platinum sponsor, DTN has created and will manage a LinkedIn page specifically for the conference – the page will serve as a real-time hub where interested parties can take a look at what company is making its presentation and when, as well as a brief profile describing the specialty of each presenting company.

This one-of-a-kind conference will feature presentations from top executives of approximately 100 life science companies focused on solutions to unmet medical needs and growth companies with disruptive technologies and business models. The panels will cover regenerative medicine, immunotherapy, diagnostics, disruptive innovations and business models, disruptive holding companies, energy – clean tech, technology media & telecom (TMT), and a discussion regarding NOLs and rights offerings.

Attendees will include more than 400 institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers, source reps and their clients. If you’re not among those privy to attend, DTN has you covered.

Visit this link to follow the investor conference page and keep up-to-date on this exciting conference:

http://dtn.fm/linkedin-scg-conference

For more information visit www.sourcecapitalconference.com

Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) is journeying into a new era in battery manufacturing. The company is broadening its horizons in its quest to become a leader in every corner of the world battery market and using novel media and communications tools, including a new website (www.oakridgeglobalenergy.com), to spread the word about its moving message.

As a manufacturer, Oakridge is in an old-fashioned business, yet the corporation approaches its operations – developing, manufacturing, marketing and selling energy storage products – in unique ways. With an estimated market capitalization of USD $250,000,000, Oakridge is doing many things right.

Oakridge fully embraces the technology, vision and capability needed to execute its expansion strategies. Using the latest technology, the company designs, develops and manufactures the high-quality cells, batteries and energy storage systems that comprise its innovative ‘Made in the USA’ product portfolio. The portfolio includes multiple lithium-ion chemistries, technologies and form factors optimized for four high-demand target markets, including:

1. Motive applications, such as electric and hybrid electric fleet vehicles (especially golf cars and local area electric vehicles);
2. Remote control and portable devices (including medical devices);
3. Starter motor batteries for motorcycles, jet skis, snow mobiles and boats, as well as cars and trucks; and
4. Stationary living space power for domestic, commercial and grid applications (homes, businesses, RVs, boats and uninterruptable power supplies).

Generally, Oakridge’s power systems and batteries also have applications in the aerospace, marine, medical, military and telecom sectors.

Oakridge is a staple in the world of integrated energy storage solutions. It has been three decades since Oakridge was established (the company was incorporated in 1986), and the company continues to improve every facet of its business. While conducting a complete review and renovation of its business and products in 2014 and 2015, the company identified its investors’ and customers’ growing demand for information on Oakridge’s revolutionary energy storage technology. To address this need for more access, the company embarked on rebranding. Now, with new, best-in-class media and communication tools, Oakridge is providing its stakeholders with improved information and keeping them engaged in the company’s activities. The tools also provide Oakridge with a distinct point of differentiation over its competition in the Far East.

For more information, visit www.oakridgeglobalenergy.com

Let us hear your thoughts: Oakridge Global Energy Solutions, Inc. Message Board

Cancer Genetics, Inc. (NASDAQ: CGIX) is focused on the development of personalized genetic testing for the detection of various cancers, with the goal of significantly increasing treatment efficacy while reducing healthcare costs. CGI’s scientific advisory board includes leaders in the areas of hematological malignancies, solid tumor cancers, pharmacogenomics, and clinical trials administration. The company’s growing patent base consists of molecular-focused patents for the diagnosis, prognosis, and risk stratification of difficult-to-treat cancers, based on what the company calls “unique algorithms that take into account multiple chromosomal regions associated with particular disease outcomes or treatment decision”.

CGI is heavily involved in the area of pharmacogenomics – determining the way genetics affects a patient’s drug response – to improve treatment and even help select trial populations for clinical testing. The company offers a number of pharmacogenomics testing services, including theranostic testing for various hematological and solid tumor cancers. In 2013, CGI helped form Oncospire Genomics as an equally owned joint venture with Mayo Clinic, designed to develop and commercialize NGS (Next Generation Sequencing) panels for unmet critical oncological needs. In 2014, CGI acquired Gentris, LLC, a pharmacogenomics testing, genotyping, and biorepository services company based in Raleigh, NC, with operations in China. That same year, the company also acquired India-based Bioserve Biotechnologies Pvt. Ltd., a leader in DNA related services in India.

Based in Rutherford, New Jersey, CGI also has operations in North Carolina and California, as well as in India and China. In addition, the company has research collaborations with cancer research and treatment leaders around the world, including:

• Beth Israel Deaconess Medical Center
• Cleveland Clinic
• Columbia University
• Groupe Hospitalier Pitié Salpétriêre, Paris
• Huntsman Cancer Institute, University of Utah
• Kamineni Hospital
• Keck Medicine of USC
• Mayo Clinic
• Memorial Sloan-Kettering Cancer Center
• Moffitt Cancer Center
• National Cancer Institute
• North Shore-Long Island Jewish Health System
• University of Alabama School of Medicine
• University of Iowa Cancer Center
• Westchester Medical Center at New York Medical College

CGI’s President and CEO is Panna Sharma, founder of TSG Partners, a specialty life sciences consultancy and advisory company, where he directed the company’s strategic initiatives and growth strategy, including various public and private company turnarounds, establishing several life science capital markets indices that are still used in the life science industry.

For more information, visit www.CancerGenetics.com.

The Clorox Company (NYSE: CLX) manufactures and markets consumer and professional products worldwide. The company operates through four segments: Cleaning, Household, Lifestyle, and International. Clorox is a global company with leading brands that have become household names, including its namesake bleach and cleaning products; Green Works naturally derived cleaning products; Ayudín and Poett home care products; Pine-Sol dilutable cleaner; Fresh Step cat litter; Kingsford charcoal; Hidden Valley and K.C. Masterpiece dressings and sauces; Brita water filtration products; Glad bags, wraps and containers; and Burt’s Bees natural personal care products.

Clorox manufactures products in more than two-dozen countries and markets them in more than 100 countries. The company offers laundry additives, including bleach products under the brand Clorox, as well as stain fighter and color booster products under the brand Clorox 2 and home care products under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands.

Clorox also provides naturally derived products under the Green Works brand name; and cleaning and disinfecting products under the Clorox, Dispatch, Aplicare, HealthLink, and Clorox Healthcare brands. In addition, the company offers plastic bags, wraps, and containers under the brand name Glad; cat litter products under the Fresh Step, Scoop Away, and Ever Clean brand names; and charcoal products under the Kingsford and Match Light brands.

In addition to the products mentioned above, Clorox provides dressings and sauces under the Hidden Valley, K.C. Masterpiece, and Soy Vay brand names; water-filtration systems and filters under the Brita brand; and natural personal care products under the Burt’s Bees brand name. Additionally, the company offers dust wipes under the brand name Clorox; facial products and lip crayons and balms under the Burt’s Bees brand; and scents under the Glad, OdorShield, and Gain brands. It also markets its products under the PinoLuz, Ayudin, Limpido, Clorinda, Poett, Mistolin, Lestoil, Bon Bril, Agua Jane, and Chux brands.

Clorox strives to make everyday life better in the parts of the world where it does business by giving back to its communities. Whether it’s contributing to disaster relief efforts through donations of Clorox regular bleach, teaching classes at local schools or funding education, arts and culture programs, Clorox is committed to helping restore, enrich and protect its communities.

For more information, please visit the company’s website at www.thecloroxcompany.com

Nike, Inc. (NYSE: NKE), headquartered in Beaverton, OR, is the world’s leading sportswear and sporting goods company, with a market cap approaching $100 billion. Founded in 1964 as Blue Ribbon Sports, and changing its name to NIKE in 1971, the company offers a full range of sports related clothing, accessories, and equipment through sports and department stores and shops worldwide, as well as directly to consumers over the Internet. Nike’s stated mission is “To bring inspiration and innovation to every athlete in the world”, adding that “if you have a body, you are an athlete”, the latter being a mantra used by legendary University of Oregon track and field coach, Bill Bowerman, who, along with Philip Knight, founded the company.

Philip H. Knight, a director of the company since 1968, is Chairman of the Board, and also served as company President for much of that time. Nike’s current CEO and President, Mark Parker, joined in 1979, using his experience as a competitive runner to design footwear for the company. Nike feels it has built its dominant position in the marketplace largely through its close connection with both the casual and professional sports community, and now serves the sports market on six continents. It continues to grow sales and market share.

In addition to its large Oregon headquarters, with over 8,000 employees, Nike has corporate locations in New York, Chicago, Los Angeles, Toronto, and Fort Worth. Its European headquarters is in the Netherlands, with operational and administrative centers in London, Paris, Frankfurt, Stockholm, Moscow, and several other locations. The Japan & Asia Pacific region is supported by key operations in Japan, Korea, India, Singapore, Malaysia, Indonesia, Vietnam, Australia, and other countries, while the Nike Greater China Campus, with nearly 2,000 employees, is located in Shanghai. Nike also employs more than 3,000 workers in Brazil, Argentina, Chile, Uruguay, Paraguay, Bolivia, and Mexico, and has operations in South Africa.

As a worldwide employer, Nike emphasizes its ongoing efforts to demand ethical working conditions from its suppliers and business partners, affirming detailed steps it continues to take to eliminate forced or bonded labor, and to incentivize changes that benefit workers throughout the supply chain. According to the company’s Standards for Compliance: “Nike uses third-party auditors to verify contracted factories are (in) compliance with laws. If a contracted factory is found to violate laws or Nike standards, it is responsible for improving performance against a master action plan. If the factory fails to make progress against that plan, they are subject to review and sanctions, including potential termination.”

For more information, visit http://investors.Nike.com/Home/default.aspx and http://about.Nike.com/

Alternet Systems, Inc. (OTCQB: ALYI) was recently identified as a “promising, undervalued emerging technology leader” in a report by Wall Street Corner. As a result, Wall Street Corner Special Report, which is hailed as the premier discovery site for promising, yet undiscovered small- and micro-cap stocks featuring opportunities in an ethical, professional and responsible manner, has engaged Caprock Research to initiate ongoing research coverage on the company. An initial report is expected to be released by the end of this month.

To view the initial release, visit http://www.wallstreetcornerreport.com/alyi-report

The report went on to praise Alternet’s history of successfully developing digital commerce technologies. Under its current management team, the company developed and sold a mobile wallet technology for $6 million, and Alternet is currently developing its next leading digital commerce technologies. With the world becoming increasingly dependent on technological conveniences and advances, Alternet is investing in verticals within the digital commerce space, transforming the legacy electronic payments infrastructure and developing advanced predictive data analytics applications for the mass consumer, as well as the telecommunications and financial industries.

Within the past two years, the company’s price per share (PPS) has climbed as high as $0.17, making its current PPS, which is under $0.02, well under the weighted two-year average PPS.

For more information, visit www.alternetsystems.com

Let us hear your thoughts: Alternet Systems, Inc. Message Board

Stellar Biotechnologies, Inc. (NASDAQ: SBOT), a California-based biotechnology company and world leader in the sustainable manufacture of keyhole limpet hemocyanin (KLH), a protein used for stimulating and measuring immune response, has announced plans to form a joint venture with Neovacs S.A., a French biotechnology company focused on an active immunotherapy technology platform.

The joint venture will be for the manufacture of conjugated therapeutic vaccines based upon Stellar’s proprietary KLH protein, specifically to produce Neovacs’ Kinoid product candidates, including IFNa-Kinoid, and to potentially produce other KLH-based immunotherapies on behalf of third party customers. However, negotiations are not complete and will continue regarding details of the venture’s exact ownership and organization, though it is anticipated that initial ownership will be 70% with Neovacs and 30% with Stellar. The announcement was also careful to make clear that there can be no assurance the joint venture will be consummated or, if consummated, will achieve the expected results.

Stellar’s Chairman and CEO, Frank Oakes, said of the proposed venture: “We believe the proposed joint venture could be a very positive development for both Stellar and Neovacs. It would enable us to work together to ensure the successful development of IFNa-Kinoid at scale but, importantly, we anticipate building manufacturing infrastructure and expertise that could be offered to other developers of conjugate vaccines looking to transition their product candidates from clinical to commercial scale. For Stellar, this is an example of leveraging our KLH core business to expand our potential clinical and commercial opportunities.”

Neovacs CEO, Miguel Sieler, added: “We look forward to working with Stellar Biotechnologies to form this cooperative venture, as they are the leading supplier of KLH protein based on sustainable, scalable aquaculture techniques. Since KLH is a key component of IFNa-Kinoid, this venture is intended to support Neovacs as we work toward potential market launch, as well as bring added value in the field of KLH-Kinoid conjugate vaccines.”

For more information, visit www.StellarBiotech.com and http://ir.StellarBiotechnologies.com.

Earlier today, View Systems, Inc. (OTC: VSYM), a manufacturer and installer of non-invasive weapons detection systems for government and commercial use, announced it has entered into a definitive agreement to acquire Y.M. Advantage, Inc. (YMA), a private corporation engaged in the acquisition, development and management of medical clinics providing treatment for various medical issues. Through this acquisition, View Systems aims to achieve greater market penetration while promoting sustainable financial growth.

“As previously announced, our exploration and execution of M&A agreements are by no means an exit from our current focus of operations,” Gunther Than, chief executive officer of View Systems, stated in the news release. “After careful selection and due diligence, we’re excited to announce our acquisition of YMA, which will help View Systems gain traction in obtaining exposure, application and market penetration of our products.”

YMA’s business model focuses primarily on the acquisition of concierge, all-inclusive medical practices, particularly those relating to issues of male sexual dysfunction – including erectile dysfunction, testosterone replacement therapy and premature ejaculation. By targeting this niche in the medical community, YMA seeks to capitalize on current market trends that are being magnified by the aging population and a sharp rise in the prevalence of certain medical conditions.

Market statistics support YMA’s strategy. According to a report by Transparency Market Research, the increasing incidence of genitourinary diseases and a shifting preference toward a sedentary lifestyle represent lucrative opportunities in the male sexual dysfunction market moving forward. The company estimates the current U.S. market for erectile dysfunction at $6 billion, and aging baby boomers are expected to provide an expanding pool of prospective clients over the next decade.

In the past, major pharmaceutical companies Pfizer (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) have led the way in the male sexual dysfunction market with Viagra and Cialis, respectively, but projections suggest that this could be set to change in the coming years. While Viagra will maintain patent exclusivity until 2020, it is one of the final holdouts in the market. As exclusivities expire, industry data suggests that there will be an opportunity for new players to grab market share with innovative new drugs addressing medical conditions that are increasingly prevalent throughout the aging population. This should ensure that YMA’s targeted medical practices remain in high demand for the foreseeable future.

“Our board of directors consists of physicians who are well versed in the medical arena and have started and successfully operated clinics and medical practices,” continued Than. “They believe that this acquisition will dramatically enhance our revenue and provide for a wider ranging business practice.”

Look for View Systems to leverage the high demand for treatments related to male sexual dysfunction in order to promote strong financial growth. By acquiring YMA and maintaining its current focus of operations, the company becomes a diversified investment opportunity with tremendous upside for prospective shareholders.

For more information, visit www.viewsystems.com

Let us hear your thoughts: View Systems, Inc. Message Board

When someone is in pain, they cannot concentrate on anything other than how to alleviate that pain as quickly as possible, and many times, Tylenol just isn’t enough. The pain associated with injury and surgery is unbearable at times, but many people are understandably cautious about getting prescription narcotics from their doctors because of the obvious habit-forming, addictive risks associated with these medications.

Nutra-Pharma Corp. (OTCQB: NPHC) offers a suitable substitute to these potentially dangerous medications with its Nyloxin product – an all-natural product aimed at treating moderate to severe chronic pain. Chronic pain is defined as pain that lasts longer than three months and may be related to certain medical conditions including diabetes, arthritis, migraines, fibromyalgia, cancer, shingles, sciatica, and previous trauma or injury.

Nyloxin is available over the counter and comes in two strengths and three forms, conditional on what is more convenient and applicable to the person in need – an oral spray, a roll-on and a topical gel. This makes choosing your remedy much easier, because some people are wary of the time it takes for pills to work and would rather have a topical application medication to go right to the source of the pain.

Nyloxin is equivalent to 300 doses of aspirin and about 1/30 of a dose of morphine. So, you have a supremely effective method of instant pain relief, literally, in the palm of your hand that has none of the addictive ramifications of morphine. Substituting an all-natural form of pain relief (Nyloxin is derived from cobra venom) for habit forming narcotics or some lower strength over the counter competitors makes more sense for treating pain in an effective, time oriented manner.

Nyloxin is also becoming available all over the world, according to a recent letter to shareholders from Nutra Pharma CEO Rik J. Deitsch. The company announced that it has received acceptance for Nyloxin from CPAM – the medical authority in China – paving the way for distribution in the world’s fastest growing consumer market. Also, Nutra Phama announced its plans to distribute Nyloxin in Canada.

For more information on the company, visit www.NutraPharma.com

Let us hear your thoughts: Nutra Pharma Corp. Message Board

According to recent analysis out late last year from the world’s second largest publisher of premium market reports, MarketsandMarkets, the global market for biomarkers is on-track to grow at a CAGR of 13.58 percent through 2020, reaching upwards of $45.55 billion on the strength of increasing healthcare, as well as R&D spending. A key driver of this growth is the massive importance of biomarkers as an objective means for calculating a pathogenic or pharmacological response to therapeutics, or to gauge the behavior of a normal biological process. Biomarker technology continues to play a pivotal role when it comes to developing cutting-edge diagnostics for ailments such as cancer.

Indeed, the global cancer biomarkers market will continue to be one of the most active segments moving forward according to M&M, and this segment is slated to run at an 11.6 percent CAGR over the same interval. Driven by major players engaged in personalized medicine and molecular diagnostics involving biomarkers, such as global microarray market leader Affymetrix (NASDAQ: AFFX), which was recently reported as having been acquired by competitor Thermo Fisher Scientific (NYSE: TMO) for approximately $1.3 billion, as well as more investor-accessible players, some of whom may have at their disposal technologies that hold the potential to reshape the industry itself.

Such high-profile M&A activity at the heart of the translational research/microarray sector speaks volumes for how hot the space has become, and how much promise it holds for the future of medicine. One of the areas in oncology diagnostics that bears consideration is ovarian cancer, due to the specific challenges and concerns associated with the space. American Cancer Society data indicates that roughly 21,300 women in the U.S. alone were diagnosed with ovarian cancer last year, leading to approximately 14,200 tragic deaths. With an overall five-year survival rate of only 45 percent, ovarian cancer is the fifth most common cause of cancer-related death among women, and the risk is highest in women over the age of 55.

Given the high five-year survivability rate of around 93 percent for ovarian cancer, if it is detected in the early stage in which the symptoms are often ignored – compared to an only 18 percent five-year survivability rate if it is detected in later stages – the benefits of advanced warning and pre-symptomatic screening using a definitive, cost-effective diagnostic test cannot be overstated. This is especially true for patients who are found to have platinum-resistant/refractory ovarian cancer, as such patients have an extremely poor prognosis and may also be classed as having chemotherapy-resistant/refractory ovarian cancer.

The standard approach to ovarian cancer utilizes the combination of a platinum compound such as Bristol-Myers Squibb’s (NYSE: BMY) (OTC: BMYMP) Platinol® (cisplatin) or Paraplatin® (carboplatin), and a Taxane, such as Sanofi’s (NYSE: SNY) Taxotere® (docetaxel), or Phyton Biotech’s Taxol® (paclitaxel). But for patients with platinum-resistant/refractory ovarian cancer, early detection is really the brass ring, even with such good news out recently as Merck (NYSE: MRK) and Pfizer (NYSE: PFE) receiving FDA approval for the first Phase III study of avelumab, an investigational, fully human PD-L1 (programmed death-ligand 1) inhibitor that could emerge as a treatment for platinum-resistant/refractory ovarian cancer.

Suffice it to say, this is a market ripe for a simplified microarray-based blood test for early detection of ovarian cancer, including tests like Avant Diagnostics’ (OTCQB: AVDX) OvaDx®, which possesses numerous advantages over the standard CA 125 protein biomarker test for ovarian cancer. Advantages include a sample size of only a few drops and the elimination of needle blood draws, factors which allow for high-volume screening throughput at even smaller facilities. A simplified test like OvaDx, which uses sample shipping and storage on room temperature blood cards and nevertheless yields definitive diagnostic results that allow for detection of early stage ovarian tumor cell development, is a real triumph for women’s health. OvaDx could be a game changer for the $2 billion plus ovarian cancer diagnostic market and might just put AVDX in the immuno-oncology pole position.

The recent announcement that AVDX has entered into an LOI with regenerative medicine, neurology and orphan disease-focused Amarantus Bioscience Holdings (OTCQX: AMBS) to merge the wholly-owned diagnostics subsidiary of Amarantus into AVDX is further proof of how hot the sector is overall. Amarantus Diagnostics’ MSPrecise®, a neuroimmunology-based sequencing assay for multiple sclerosis, also adds mightily to AVDX’s already promising diagnostics footprint. The $1 billion market potential possible in addressing the woefully inaccurate diagnostics market for multiple sclerosis stands to make the combined company a force to be reckoned with. Adding to this emerging diagnostic juggernaut’s appeal is the $3 billion potential of Amarantus Diagnostics’ LymPro Test® for Alzheimer’s disease, another early detection-focused marvel that could revolutionize treatment options for Alzheimer’s patients.

For more information, visit www.avantdiagnostics.com

Let us hear your thoughts: Avant Diagnostics, Inc. Message Board